The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Drop today was due to going Ex Divi but personally was overcooked . Happy to add and wait
Yup skullduggery going on, no reason for drop only games, world markets all up, it'll find its footing.
Markets can be very irrational. No company news, no change in the fundamental outlook - yesterday they were one of the biggest risers, today one of the biggest fallers.
Positive start to year with encouraging recent results. Brokers are still positive and even a slight nudge up on target price from Berenberg. End of April for next update
I think this is the norm for UK shares - good companies with good ideas (ie. cheap medicines for all) are punished. In the US they are celebrated.
I am down in this share. Why?
Imo the boys in the city need to make a living so they manipulate the share price up and down to take away people's ISA/pension money. The net effect for say a car mechanic when he retires is that he is lucky to get his/her money back.
It is far better in the US market...and best to leave these clowns to ruin their opportunity to make our lives better with our money.
Does anyone understand the reason for this? We had the results - very well received, all comments I read were supportive, the share price went up as expected, now it's tumbling.
Another fine set of results,rewarding those who have consistently believed this to be a sound company despite some strange dips in the sp
Another underperformer due to the illiquid London market...better to be in the US market.
HIK should be in the region of p/e 13.3 x eps 169.7p = £22.56 - if it was listed in the US.
Time for another takeover like Hotel Chocolat !!!
Invested here on good positive momentum. I've done well with HIK in the past with gains of 29%, 1% and a loss of 7%. I hold for 1 year.
Nick2723, A very impressive list of very positive results all round. Can see no reason why the sp should not keep going higher. Have been with Hikma for a long time now. The sp has been very volatile,but for me it is a share to stay with and enjoy.
Strong first half performance
· Group revenue up 18% with strong growth in all three business segments
· Reported gross margin of 50.1%, reflecting favourable product mix
· Core operating profit up 35% to $401 million, reflecting H1 weighting of Generics and Branded
· Good net cash inflow from operating activities, up 31% to $222 million
· Robust balance sheet with net debt4 to core EBITDA5 of 1.3x at 30 June 2023 (31 December 2022 1.5x)
· Interim dividend of 25 cents per share, up 32%
Growth in all three businesses
· Global Injectables revenue growth of 9%, reflecting a good top-line performance in all markets, including full period contribution from a recent acquisition. A core operating profit margin of 36.6%
· Branded had a strong first half with 11% revenue growth and 41% core operating profit growth, reflecting a good performance across our markets and the early fulfilment of some tenders
· Generics revenue growth of 39% and core operating profit growth of 110%, reflecting a stronger-than-expected performance across the base portfolio and our six-month exclusivity for the authorised generic of sodium oxybate
I would hope the SP will be far stronger now after these results. What do others think?
In automatic Promotion spot now.
You know what that means....
"Hikma Pharmaceuticals rose 5.3%, as it reported a dip in annual revenue" but ended the day down.
It's had a great run lately - recovering from being hugely oversold in my mind; but I think it's getting closer to fair value. There may still be a bit more room to the upside. I think it more likely to edge higher than lower over the coming weeks.
Hikma Pharmaceuticals rose 5.3%, as it reported a dip in annual revenue while profit tumbled, but shared a more positive outlook for the current year.
Revenue edged down 1% to USD2.52 billion from USD2.55 billion, but pretax profit dropped to USD233 million from USD544 million.
This was due to an impairment in its Generics business. Hikma noted a strong performance from Injectables and Branded businesses, which helped to partially offset the Generics decline. The annual dividend was lifted by 4% to 56 cents.
"Looking ahead, we are confident that we will deliver good growth across all three of our businesses in 2023," said Chair & CEO Said Darwazah.
Very .encouraging broker reports from Credit Suisse & R B C & Jefferies Over the last little while. Is now the time to top up one`s holding
Hikma Pharmaceuticals reiterated annual guidance for all three of its businesses. "We are seeing strong momentum in our Branded and Injectables businesses, reflecting the benefits of their increasingly broad and differentiated product portfolios, leading market positions and our flexible high-quality manufacturing footprint," the company said. It noted the US generic market remains competitive, but its Generics business is performing in line with previous guidance. Hikma noted the impact of inflation on costs, and now expects a core net finance expense of USD74 million compared to previous guidance of USD68 million, due to increasing interest rates. The search for a new CEO remains on track, it said.
What looked like a promising rally has all but been wiped out, very disappointing.
I agree that 1.8m trade volume does not explain the big rise today.
"Volumes for the day may indicate if someone has started accumulating. I expect the volumes to be a lot higher than normal."
1,8m v average of 600k, so about 3 times average - when you get such a big move volumes tend to be higher anyway, so I'm not convinced it indicates a big buyer.
... mooted...
Anyone wanting to buy this would not get it at this sort of price. 30% ownership in the Darwazah family, they would surely block any takeover at this price. I think a minimum takeover price of £22 was muted when rumours started a few years ago. I got in yesterday as it was starting to look bullish to me, wish I had put more in:( Let's hope this rally holds, but setting some stop loses just in case it pulls back.
This share has stood out like a sore thumb all day and the continued rise does make you wonder what is going on.
Volumes for the day may indicate if someone has started accumulating. I expect the volumes to be a lot higher than normal.
and HIK earnings are in USA dollars and dollar been so strong all looking good